Table 5. Prognostic factors for... | American Society of Hematology

Table 5.

Prognostic factors for disease-free and overall survival (months) for patients randomized to postremission therapy

Variable	Category	n	Survival, median (95% CI)	P	DFS, median (95% CI)	P
Treatment	Ara-C	82	20 (15, 24)	.90	11 (9, 13)	.67
	Ara-C + M	87	16 (14, 24)		10 (8, 14)
Age, y	60-69	96	20 (15, 27)	.52	10 (8, 15)	.54
	≥ 70	73	19 (15, 22)		11 (9, 13)
WBC	< 30	122	21 (19, 29)	.001	13 (10, 17)	< .001
	≥ 30	43	13 (11, 19)		8 (6, 9)
Platelet count	< 50	102	16 (14, 20)	.10	9 (8, 12)	.13
	≥ 50	63	25 (19, 32)		14 (11, 19)
Cytogenetics^5-150	CBF	6	11 (11, 24)	.78^5-151	7 (6, 9)	.06^5-151
	Other abnormal	40	19 (13, 29)	.61^5-151	9 (8, 16)	.66^5-151
	Normal	57	16 (14, 27)		10 (8, 15)
Immunophenotype	CD56⁻	69	21 (16, 29)	.006	12 (9, 15)	.04
	CD56⁺	6	12 (10, 16)		8 (6, 8)

Variable	Category	n	Survival, median (95% CI)	P	DFS, median (95% CI)	P
Treatment	Ara-C	82	20 (15, 24)	.90	11 (9, 13)	.67
	Ara-C + M	87	16 (14, 24)		10 (8, 14)
Age, y	60-69	96	20 (15, 27)	.52	10 (8, 15)	.54
	≥ 70	73	19 (15, 22)		11 (9, 13)
WBC	< 30	122	21 (19, 29)	.001	13 (10, 17)	< .001
	≥ 30	43	13 (11, 19)		8 (6, 9)
Platelet count	< 50	102	16 (14, 20)	.10	9 (8, 12)	.13
	≥ 50	63	25 (19, 32)		14 (11, 19)
Cytogenetics^5-150	CBF	6	11 (11, 24)	.78^5-151	7 (6, 9)	.06^5-151
	Other abnormal	40	19 (13, 29)	.61^5-151	9 (8, 16)	.66^5-151
	Normal	57	16 (14, 27)		10 (8, 15)
Immunophenotype	CD56⁻	69	21 (16, 29)	.006	12 (9, 15)	.04
	CD56⁺	6	12 (10, 16)		8 (6, 8)

For abbreviations, see Tables 2 and 3.

See text.

P values are from comparisons with the normal group.